Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target raised by equities research analysts at Barclays from $617.00 to $626.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the pharmaceutical company’s stock. Barclays‘s target price would indicate a potential upside of 14.53% from the company’s current price.
Several other research firms have also weighed in on VRTX. Wells Fargo & Company lifted their price target on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a research report on Tuesday. Rothschild & Co Redburn raised their price objective on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. TD Cowen boosted their target price on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a report on Tuesday. The Goldman Sachs Group upped their target price on shares of Vertex Pharmaceuticals from $654.00 to $725.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Truist Financial increased their price target on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $596.44.
Check Out Our Latest Report on VRTX
Vertex Pharmaceuticals Stock Performance
Shares of NASDAQ VRTX traded up $15.81 during midday trading on Wednesday, hitting $546.57. 883,254 shares of the company traded hands, compared to its average volume of 1,391,682. Vertex Pharmaceuticals has a 12-month low of $406.67 and a 12-month high of $568.67. The firm has a market cap of $138.72 billion, a P/E ratio of 35.26, a P/E/G ratio of 2.65 and a beta of 0.28. The stock has a 50-day moving average price of $522.98 and a 200 day moving average price of $480.37.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 22.40% and a net margin of 30.70%. The business’s quarterly revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the business earned $4.80 earnings per share. As a group, equities analysts expect that Vertex Pharmaceuticals will post 16.74 earnings per share for the current year.
Institutional Trading of Vertex Pharmaceuticals
Several institutional investors have recently bought and sold shares of the company. Gryphon Financial Partners LLC lifted its position in Vertex Pharmaceuticals by 1.8% in the 3rd quarter. Gryphon Financial Partners LLC now owns 1,878 shares of the pharmaceutical company’s stock valued at $982,000 after acquiring an additional 34 shares in the last quarter. Kestra Investment Management LLC increased its holdings in shares of Vertex Pharmaceuticals by 10.3% in the 3rd quarter. Kestra Investment Management LLC now owns 760 shares of the pharmaceutical company’s stock worth $398,000 after purchasing an additional 71 shares in the last quarter. AlphaCore Capital LLC raised its stake in shares of Vertex Pharmaceuticals by 10.5% in the third quarter. AlphaCore Capital LLC now owns 3,599 shares of the pharmaceutical company’s stock worth $1,881,000 after purchasing an additional 341 shares during the last quarter. Leuthold Group LLC raised its stake in shares of Vertex Pharmaceuticals by 9.4% in the third quarter. Leuthold Group LLC now owns 17,113 shares of the pharmaceutical company’s stock worth $8,947,000 after purchasing an additional 1,473 shares during the last quarter. Finally, Joseph Group Capital Management lifted its holdings in shares of Vertex Pharmaceuticals by 3.1% during the third quarter. Joseph Group Capital Management now owns 11,085 shares of the pharmaceutical company’s stock valued at $5,795,000 after purchasing an additional 329 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.
More Vertex Pharmaceuticals News
Here are the key news stories impacting Vertex Pharmaceuticals this week:
- Positive Sentiment: Third-quarter revenue rose 12% year over year to $3.44 billion, topping estimates, as cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributed to growth. Vertex raised its 2026 revenue outlook to $13.15 billion–$13.25 billion. Article: Vertex Pharmaceuticals Q3 Earnings Call Highlights
- Positive Sentiment: Povetacicept, a potential treatment for IgA nephropathy, is approaching an FDA decision expected November 30. Management expressed confidence in the program and launch preparations, making it an important potential growth driver beyond cystic fibrosis. Article: Vertex, ahead of FDA decision, calms fears surrounding kidney drug
- Positive Sentiment: Analyst sentiment was broadly constructive, with several firms raising price targets after the report; RBC also pointed to possible further appreciation if povetacicept is approved and launched. Article: Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept
- Negative Sentiment: Adjusted earnings of $4.76 per share missed analyst expectations, despite the revenue beat. Higher launch-related spending and costs associated with the Crinetics acquisition pressured profitability. Article: VRTX’s Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
- Negative Sentiment: Reports also highlighted lighter-than-hoped-for sales of the pain drug JOURNAVX, raising questions about the pace of growth from newer products. That concern, alongside the earnings shortfall, helps explain the mixed market reaction to results. Article: Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.
Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.
Further Reading
- Five stocks we like better than Vertex Pharmaceuticals
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
